Innate Pharma (Innate Pharma) EV-to-Revenue : 2.62 (As of May. 12, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Innate Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Innate Pharma's enterprise value is $147.83 Mil. Innate Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $56.35 Mil. Therefore, Innate Pharma's EV-to-Revenue for today is 2.62.

The historical rank and industry rank for Innate Pharma's EV-to-Revenue or its related term are showing as below:

IPHA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.08 Med: 6.2 Max: 818.54
Current: 2.51

During the past 13 years, the highest EV-to-Revenue of Innate Pharma was 818.54. The lowest was 0.08. And the median was 6.20.

IPHA's EV-to-Revenue is ranked better than
77% of 1039 companies
in the Biotechnology industry
Industry Median: 8.37 vs IPHA: 2.51

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-12), Innate Pharma's stock price is $2.53. Innate Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.70. Therefore, Innate Pharma's PS Ratio for today is 3.61.

Innate Pharma EV-to-Revenue Historical Data

The historical data trend for Innate Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma EV-to-Revenue Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.93

2.51

22.97

4.08

3.07

Innate Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															22.97	-	4.08	-	3.07

Competitive Comparison of Innate Pharma's EV-to-Revenue

For the Biotechnology subindustry, Innate Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Innate Pharma's EV-to-Revenue falls into.

Innate Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Innate Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	147.825	/	56.349
	=	2.62

Innate Pharma's current Enterprise Value is $147.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innate Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $56.35 Mil.

Innate Pharma (NAS:IPHA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Innate Pharma's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.53	/	0.701
	=	3.61

Innate Pharma's share price for today is $2.53.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.70.

Innate Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Innate Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma (Innate Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (NAS:IPHA) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

IPHYF:USA 0EVI:UK IPH:France IDDA:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.